Editorial
doi: 10.1158/1078-0432.CCR-22-0750.
Biomarker Development: Bedside to Bench
- PMID: 35481871
- DOI: 10.1158/1078-0432.CCR-22-0750
Item in Clipboard
Editorial
Biomarker Development: Bedside to Bench
Clin Cancer Res.
.
Abstract
This commentary complements the report from Nixon and colleagues by addressing the critical definitions, assay and analytical quality control and interpretation, and resources available to advance similar fit-for-purpose biomarker development. See related articles by Nixon et al., p. 2771 and 2779.
©2022 American Association for Cancer Research.
Comment on
-
Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance).Clin Cancer Res. 2022 Jul 1;28(13):2771-2778. doi: 10.1158/1078-0432.CCR-21-2386. Clin Cancer Res. 2022. PMID: 34965953 Free PMC article.
-
Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance).Clin Cancer Res. 2022 Jul 1;28(13):2779-2788. doi: 10.1158/1078-0432.CCR-21-2389. Clin Cancer Res. 2022. PMID: 34965954 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
